158 related articles for article (PubMed ID: 7919549)
21. Combined cytotoxic action of Viscum album agglutinin-1 and anticancer agents against human A549 lung cancer cells.
Siegle I; Fritz P; McClellan M; Gutzeit S; Mürdter TE
Anticancer Res; 2001; 21(4A):2687-91. PubMed ID: 11724340
[TBL] [Abstract][Full Text] [Related]
22. Short-term exposure of cancer cells to micromolar doses of paclitaxel, with or without hyperthermia, induces long-term inhibition of cell proliferation and cell death in vitro.
Michalakis J; Georgatos SD; de Bree E; Polioudaki H; Romanos J; Georgoulias V; Tsiftsis DD; Theodoropoulos PA
Ann Surg Oncol; 2007 Mar; 14(3):1220-8. PubMed ID: 17206477
[TBL] [Abstract][Full Text] [Related]
23. Combinations of paclitaxel and etoposide in the treatment of lung cancer.
Perez EA; Buckwalter CA; Reid JP
Semin Oncol; 1996 Dec; 23(6 Suppl 15):21-5. PubMed ID: 8996593
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer.
von Pawel J; Wagner H; Niederle N; Heider A; Koschel G; Hecker D; Hanske M
Semin Oncol; 1996 Dec; 23(6 Suppl 16):47-50. PubMed ID: 9007121
[TBL] [Abstract][Full Text] [Related]
25. Paclitaxel sensitization of multidrug-resistant cells to chemotherapy is independent of the cell cycle.
Locke V; Davey R; Davey M
Cytometry; 2001 Mar; 43(3):170-4. PubMed ID: 11170102
[TBL] [Abstract][Full Text] [Related]
26. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
27. Preliminary results of a phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer.
Sørensen JB; Wedervang K; Dombernowsky P
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-18-S12-20. PubMed ID: 9331114
[TBL] [Abstract][Full Text] [Related]
28. Paclitaxel-induced modification of the effects of radiation and alterations in the cell cycle in normal and tumor mammalian cells.
Gorodetsky R; Levdansky L; Ringel I; Vexler A
Radiat Res; 1998 Sep; 150(3):283-91. PubMed ID: 9728657
[TBL] [Abstract][Full Text] [Related]
29. Cytotoxicity of paclitaxel in combination with cisplatin and a new Pt-mercaptopyridine complex.
Ragazzi E; D'Ancona S; Berti E; Carrara M
Anticancer Res; 2002; 22(5):2783-8. PubMed ID: 12529997
[TBL] [Abstract][Full Text] [Related]
30. In vitro schedule-dependent interaction between paclitaxel and cisplatin in human carcinoma cell lines.
Kano Y; Akutsu M; Tsunoda S; Suzuki K; Yazawa Y
Cancer Chemother Pharmacol; 1996; 37(6):525-30. PubMed ID: 8612305
[TBL] [Abstract][Full Text] [Related]
31. High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study.
Bengala C; Danesi R; Guarneri V; Pazzagli I; Donati S; Favre C; Fogli S; Biadi O; Innocenti F; Del Tacca M; Mariani M; Conte PF
Bone Marrow Transplant; 2003 Feb; 31(4):275-80. PubMed ID: 12621462
[TBL] [Abstract][Full Text] [Related]
32. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
[TBL] [Abstract][Full Text] [Related]
33. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
Gershenson DM; Morris M; Burke TW; Levenback C; Wolf J; Lee JJ; Thall PF; Atkinson EN; Silva EG; Wharton JT
Cancer; 1999 Dec; 86(11):2291-300. PubMed ID: 10590370
[TBL] [Abstract][Full Text] [Related]
34. In vitro test-system for chemo- and thermosensitivity: an analysis of survival fractions and cell-cycle distributions in human Ewing's sarcomas as a modelfor tumors in pediatric oncology.
Debes A; Rommel F; Breise M; Willers R; Göbel U; Wessalowski R
Klin Padiatr; 2002; 214(4):223-9. PubMed ID: 12165906
[TBL] [Abstract][Full Text] [Related]
35. Paclitaxel couplets with cyclophosphamide or cisplatin in metastatic breast cancer.
Tolcher AW
Semin Oncol; 1996 Feb; 23(1 Suppl 1):37-43. PubMed ID: 8629035
[TBL] [Abstract][Full Text] [Related]
36. In vitro schedule-dependent interaction between paclitaxel and oxaliplatin in human cancer cell lines.
Tanaka R; Ariyama H; Qin B; Takii Y; Baba E; Mitsugi K; Harada M; Nakano S
Cancer Chemother Pharmacol; 2005 Jun; 55(6):595-601. PubMed ID: 15731917
[TBL] [Abstract][Full Text] [Related]
37. Effect of selenium in combination with Adriamycin or Taxol on several different cancer cells.
Vadgama JV; Wu Y; Shen D; Hsia S; Block J
Anticancer Res; 2000; 20(3A):1391-414. PubMed ID: 10928049
[TBL] [Abstract][Full Text] [Related]
38. Three-dimensional culture system as a model for studying cancer cell invasion capacity and anticancer drug sensitivity.
Doillon CJ; Gagnon E; Paradis R; Koutsilieris M
Anticancer Res; 2004; 24(4):2169-77. PubMed ID: 15330157
[TBL] [Abstract][Full Text] [Related]
39. Sequence-dependent cytotoxicity of etoposide and paclitaxel in human breast and lung cancer cell lines.
Perez EA; Buckwalter CA
Cancer Chemother Pharmacol; 1998; 41(6):448-52. PubMed ID: 9554587
[TBL] [Abstract][Full Text] [Related]
40. Taxol in combination with doxorubicin or etoposide. Possible antagonism in vitro.
Hahn SM; Liebmann JE; Cook J; Fisher J; Goldspiel B; Venzon D; Mitchell JB; Kaufman D
Cancer; 1993 Nov; 72(9):2705-11. PubMed ID: 8104682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
